IL17A and psoriasis: Additionally, a BTK inhibitor was discovered to decrease imiquimod (IMQ)-induced psoriasis-like inflammation by modulating IL-23/IL-17A in innate immune cells [25], establishing a physiological link involving immune control and symptom alleviation.